Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Elevated plasma FFA cause β-cell lipotoxicity and impair insulin secretion in nondiabetic subjects predisposed to type 2 diabetes mellitus [T2DM; i.e., with a strong family history of T2DM (FH+)] but not in nondiabetic subjects without a family history of T2DM. To determine whether lowering plasma FFA with acipimox, an antilipolytic nicotinic acid derivative, may enhance insulin secretion, nine FH+ volunteers were admitted twice and received in random order either acipimox or placebo (double-blind) for 48 h. Plasma glucose/insulin/C-peptide concentrations were measured from 0800 to 2400. On day 3, insulin secretion rates (ISRs) were assessed during a +125 mg/dl hyperglycemic clamp. Acipimox reduced 48-h plasma FFA by 36% ( P < 0.001) and increased the plasma C-peptide relative to the plasma glucose concentration or ΔC-peptide/Δglucose AUC (+177%, P = 0.02), an index of improved β-cell function. Acipimox improved insulin sensitivity (M/I) 26.1 ± 5% ( P < 0.04). First- (+19 ± 6%, P = 0.1) and second-phase (+31 ± 6%, P = 0.05) ISRs during the hyperglycemic clamp also improved. This was particularly evident when examined relative to the prevailing insulin resistance [1/(M/I)], as both first- and second-phase ISR markedly increased by 29 ± 7 ( P < 0.05) and 41 ± 8% ( P = 0.02). There was an inverse correlation between fasting FFA and first-phase ISR ( r 2= 0.31, P < 0.02) and acute (2–4 min) glucose-induced insulin release after acipimox ( r 2=0.52, P < 0.04). In this proof-of-concept study in FH+ individuals predisposed to T2DM, a 48-h reduction of plasma FFA improves day-long meal and glucose-stimulated insulin secretion. These results provide additional evidence for the important role that plasma FFA play regarding insulin secretion in FH+ subjects predisposed to T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 2×
“Subjects genetically predisposed to T2DM are insulin resistant, and insulin secretion is best represented in relation to the degree of insulin resistance (11, 12, 15, 20, 23, 26, 28, 29, 30, 46, 50).”
BackgroundA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 1×
“, phosphoenolpyruvate carboxykinase [PEPCK] and glyceraldehyde-3-phosphate dehydrogenase [GPDH]) as well as FFA uptake and reesterification (6), increasing plasma adiponectin levels [which were low and unchanged by acipimox treatment in this cohort of insulinresistant FH subjects (data not shown)] (5), and improving F…”
BackgroundSelf-citationRole of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM
Boden, G. (1997) · Diabetes · doi:10.2337/diab.46.1.3 · Cited by 1,728
Lillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508 · cited 4×
“Excessive rates of lipid turnover have been shown to precede the development of T2DM in FH subjects (23, 30, 46) and in nondiabetic obese individuals (10, 29).”
BackgroundInfluentialMcGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications
Unger, R. H. (1995) · Diabetes · doi:10.2337/diab.44.8.863 · Cited by 1,100
Effect of fatty acids on glucose production and utilization in man.
Ferrannini, E., Barrett, E. J., Bevilacqua, S., & DeFronzo, R. A. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111133 · Cited by 1,050
Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., & Groop, L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210601 · Cited by 807 · cited 2×
“Subtle defects in -cell function and insulin resistance precede the development of hyperglycemia in individuals at high risk of developing T2DM, including subjects with a strong family history of T2DM (FH ) (2–4), obese subjects (10, 46), individuals with impaired glucose tolerance (20, 30), and women with polycystic…”
BackgroundZhou, Y. P., & Grill, V. E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117042 · Cited by 677 · cited 1×
“Elevation in the plasma FFA causes hepatic and skeletal muscle insulin resistance in healthy individuals (8, 15, 27, 33), and exposure to pharmacological levels of lipids for more than 24–48 h impairs -cell function in vitro (54) and in vivo (9, 19, 39).”
BackgroundFerrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540 · cited 1×
“Therefore, we also examined -cell function as the relationship between plasma C-peptide and glucose concentration during the 48-h administration of acipimox or placebo as an index of insulin secretion dose response to the prevailing plasma glucose concentration, also known as -cell glucose sensitivity (22).”
BackgroundSelf-citationKashyap, S., Belfort, R., Gastaldelli, A., Pratipanawatr, T., Berria, R., Pratipanawatr, W., Bajaj, M., Mandarino, L., DeFronzo, R., & Cusi, K. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2461 · Cited by 503
Self-citationXiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Kawakubo, M., & Buchanan, T. A. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1066 · Cited by 402
Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome
Lewy, V. D., Danadian, K., Witchel, S. F., & Arslanian, S. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.109603 · Cited by 298 · cited 2×
“Subtle defects in -cell function and insulin resistance precede the development of hyperglycemia in individuals at high risk of developing T2DM, including subjects with a strong family history of T2DM (FH ) (2–4), obese subjects (10, 46), individuals with impaired glucose tolerance (20, 30), and women with polycystic…”
BackgroundGulli, G., Ferrannini, E., Stern, M., Haffner, S., & DeFronzo, R. A. (1992) · Diabetes · doi:10.2337/diab.41.12.1575 · Cited by 283
Effects of a 48-h Fat Infusion on Insulin Secretion and Glucose Utilization
Boden, G., Chen, X., Rosner, J., & Barton, M. (1995) · Diabetes · doi:10.2337/diab.44.10.1239 · Cited by 271
Paolisso, G., Gambardella, A., Amato, L., Tortoriello, R., D'Amore, A., Varricchio, M., & D'Onofrio, F. (1995) · Diabetologia · doi:10.1007/bf00401761 · Cited by 217
Relationship between insulin-mediated glucose disposal and lipid metabolism in man.
Lillioja, S., Bogardus, C., Mott, D. M., Kennedy, A. L., Knowler, W. C., & Howard, B. V. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111804 · Cited by 150 · cited 2×
“Excessive rates of lipid turnover have been shown to precede the development of T2DM in FH subjects (23, 30, 46) and in nondiabetic obese individuals (10, 29).”
BackgroundBajaj, M., Suraamornkul, S., Kashyap, S., Cusi, K., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0224 · Cited by 109
Self-citation
Cited by
Glucolipotoxicity: fuel excess and β-cell dysfunction
Poitout, V., & Robertson, R. P. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0023 · Cited by 1,092
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Self-citationBoden, G. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.06.007 · Cited by 853
Obesity, insulin resistance and free fatty acids
Boden, G. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283444b09 · Cited by 848
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451
Self-citation
Metadata
- Authors
- Cusi, K., Kashyap, S., Gastaldelli, A., Bajaj, M., & Cersosimo, E.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2007-06
- Volume
- 292
- Issue
- 6
- Pages
- E1775-E1781
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2066743086
- Cited by
- 105
- References
- 19
- FWCI
- 10.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.